Professor, Associate Chair for Research

400 Monroe Ave NW
(616) 234-2841

André S. Bachmann, Ph.D., M.S., is a Michigan State University (MSU) Professor and Associate Chair for Pediatric Research with tenure in the College of Human Medicine's Department of Pediatrics and Human Development. He studies the therapeutic potential of polyamine inhibitors and proteasome inhibitors in cancer patients. Much of his research has provided new insights into the pediatric cancer neuroblastoma. Dr. Bachmann's ongoing study of ornithine decarboxylase (ODC) -- a protein often over-expressed in cancer -- has shown that the ODC inhibitor DFMO induces death in neuroblastoma cancer cells (Oncogene, 2005). In collaboration with the Spectrum Health Helen DeVos Children’s Hospital in Grand Rapids MI and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC; aka Beat Childhood Cancer), Dr. Bachmann has advanced his preclinical research of DFMO through a phase I clinical trial (PLoS One, 2015). Additional DFMO trials are ongoing including a phase I/II trial with DFMO/bortezomib (NCT02139397) and a phase II trial to assess the value of DFMO as an agent to prevent relapse in neuroblastoma patients (NCT02679144). Dr. Bachmann’s preclinical work motivated other clinical groups including the New Approaches to Neuroblastoma Therapy (NANT) consortium (NCT02030964) and most recently the Children’s Oncology Group (COG) to assess DFMO as a therapeutic option for children with neuroblastoma. New DFMO drug combinations and cancer pathways are investigated in the Bachmann lab, including SPR inhibitor sulfasalazine (BMC Cancer, 2015) and DHPS inhibitor GC7 (Biochemical Journal, 2018). A transgenic eIF5A1/2 CRISPR-based mouse model has been developed to study the role of DHPS-mediated hypusine activation of eIF5A1 and eIF5A2 in tumor development.

Also of interest to the Bachmann Lab are cellular mechanisms that engage the proteasome in the development of neuroblastoma, multiple myeloma, and renal cell carcinoma. In collaboration with his colleagues in Europe, Dr. Bachmann discovered the Syrbactin class of proteasome inhibitors (Nature, 2008), a natural product for which he holds several patents. TIR-199 is the best-in-class synthetic lead compound (Journal of Biological Chemistry, 2016) currently in preclinical development at Hibiskus BioPharma, Inc., a company that Dr. Bachmann co-founded with Dr. Michael Pirrung (UC Riverside). Previous work in the Bachmann lab also involved significant work with PRAF2 (JM4), a 4TM protein enriched in the brain synapses, which has prognostic value in neuroblastoma (Clinical Cancer Research, 2007).

bachmann lab photo

Education & Training

  • MS, Microbiology, University of Zürich/ETH Zürich, Switzerland, 1994

  • PhD, Biology, University of Zürich, Switzerland, 1998

  • Postdoctoral Fellow, Molecular Oncology & Virology, University of Zürich, Switzerland, 1998-1999

Selected Grants

  • R21, National Cancer Institute Grant (NCI), NIH, 2018-2020

  • St. Balderick's Foundation Research Grant, 2018-2019

  • ADVANCE Grant, 2017-2019

  • SHORA Grant, 2017-2019

  • MDG Grant, 2017-2018

  • HDVCH MODS Grant, 2017-2018

  • HDVCH Osteosarcoma Grant, 2017-2019

Past Awards (Selected)
  • R01, National Cancer Institute (NCI), NIH

  • Wipe Out Kids Cancer (WOKC) Grant

  • ARRA/R01 Grant, National Cancer Institute (NCI), NIH

  • CURE/R01 Grant, National Cancer Institute (NCI), NIH

  • R43, National Institute of Allergy and Infectious Disease (NIAID), NIH

  • Hawaii Community Foundation (HCF)

  • Magic Water Foundation

  • Weinman Foundation

Selected Peer-Reviewed Publications

  • Oncogene, 2005, 24(36):5606-18

  • Clinical Cancer Research, 2007, 13(21):6312-9

  • Cancer Research, 2008, 68(23):9825-31

  • Nature, 2008, 452(7188):755-8

  • Molecular Cancer Therapeutics, 2009, 8(7):2067-75

  • PNAS, 2009, 106(16):6507-12

  • International Journal of Cancer, 2010, 126(9):2012-24

  • Cancer Science, 2010, 101(7):1624-31

  • Biochemistry, 2012, 51(34):6880-8

  • Journal of Molecular Biology, 2014, 426(2):332-46

  • Cellular Oncology, 2014, 37(6):387-98

  • PLoS One, 2015, 10(5):e0127246

  • BMC Cancer, 2015, 15:477

  • Journal of Biological Chemistry, 2016, 291:8350-62

  • PLoS One, 2017, 12(12):e0189044

  • Bioorganic & Medicinal Chemistry, 2018, 26(2):401-12

  • Biochemical Journal, 2018, 475(2):531-45

  • Journal of Biological Chemistry, 2018, 293: 18757-69

Awards & Honors

  • Swiss National Science Foundation Award, 1994

  • Siemens National Mentor Award, 2007

  • Inaugural Weinman Award for Translational Research, 2010

Lab Directory

André S. Bachmann, PhD
André S. Bachmann, PhD
Professor; Associate Chair for Research
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chad Schultz, BS
Chad Schultz, BS
Research Assistant II
This email address is being protected from spambots. You need JavaScript enabled to view it.